ORYZON Announces New Grant from Alzheimer’s Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug

BARCELONA, SPAIN and CAMBRIDGE MA.

• ADDF to increase its stake in the company to reach 0.77 % of the common stock

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Board of Directors of the Alzheimer’s Drug Discovery Foundation (ADDF) has approved a grant of $300,000 to Oryzon Genomics S.A. in support of the project “Clinical development of a companion marker for treatment with the dual LSD1/MAO-B inhibitor ORY-2001”.

 

Click here to see the full Press Release